Bristol-Myers Squibb reports slight increase in second-quarter sales

Share this article:

Despite increased competition from generics, Bristol-Myers Squibb (BMS) reported a slight increase in its second-quarter sales results.

Second-quarter net sales were at $4.9 billion, up 1% over the same period a year earlier.

Sales of BMS' blood thinner Plavix, the company's top-selling drug, rebounded after a generic version made by Canadian generics company Apotex briefly entered the US market late last year.

Plavix sales were up 3.8% to $1.1 billion in the second-quarter from $1.0 billion.
 
A federal court judge recently upheld Plavix's patent exclusivity until 2011.

Plavix was the No. 2 selling drug behind Pfizer's Lipitor in 2005, with global sales of $5.9 billion.  
Second-quarter sales of schizophrenia drug Abilify were up 27% to $412 million.
 
Sales of AIDS drug Reyataz were rose 7.6% to $254 million.
 
Hypertension drugs Avapro and Avalide posted a combined 6.1% increase to $297 million.
 
Meanwhile, sales of oncology drug Erbitux dropped 5.8% to $162 from $172 million a year earlier. BMS pays royalties to ImClone Systems on Erbitux. Both companies recently announced that a late-stage study of the drug in lung-cancer patients didn't meet the primary endpoint of progression-free survival.

The company's once popular cholesterol drug Pravachol, which lost patent protection in April 2006, saw its sales shrink by 59% in the second-quarter to $132 million from $323 million in the year earlier period.  

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Judge blocks FDA bid to allow generic Precedex

Judge blocks FDA bid to allow generic Precedex

The US District Court for Maryland granted Hospira a temporary restraining order (TRO) against FDA, after the agency determined that potential generic competitors of the company's injectable sedation drug Precedex ...

GSK drug gets aplastic anemia indication

GSK drug gets aplastic anemia indication

Promacta was previously indicated for chronic immune thrombocytopenia.

Five things for Pharma Marketers to know: Wednesday, August 27

Five things for Pharma Marketers to know: Wednesday, ...

Allergan sets a shareholder voting date, Novo describes the types of acquisitions it will consider, and the AstraZeneca-Pfizer talks can now reopen.